Search Results - evan+abt

3 Results

Sort By:

Novel Host-Directed Therapeutic Agent to Cure Infectious Diseases (UCLA Case No. 2023-079)

UCLA researchers in Department of Molecular and Medical Pharmacology, in collaboration with Hannover Medical School in Germany, have developed a host-directed therapeutic agent targeting mammalian deoxycytidine kinase to prevent, treat, and even cure any local and systemic infectious diseases in human and animal hosts. BACKGROUND: Many clinically...

Published: 7/30/2024 | Inventor(s): Caius Radu, Evan Abt, Volker Achim Winstel

Keywords(s):

Category(s): Therapeutics > Infectious Diseases

2019-523 PROTEIN KINASE INHIBITORS WHICH ALSO TARGET DIHYDROOROTATE DEHYDROGENASE

SUMMARY: Researchers from UCLA’s Department of Molecular and Medicinal Pharmacology have discovered two protein kinase inhibitors that effectively inhibit dihydroorotate dehydrogenase, an enzyme linked to cancer progression. BACKGROUND: During the progression of cancer, normal healthy cells undergo mutation that converts normal cell phenotypes...

Published: 9/5/2023 | Inventor(s): Caius Radu, Evan Abt, Ethan Rosser

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Oncology > Oncology (Small Molecules)

Impaired Nucleotide Catabolism Renders Cancer Cells Sensitive to PNP Inhibition

UCLA researchers in the Department of Molecular and Medical Pharmacology have uncovered novel biomarkers to predict cancer sensitivity to PNP inhibitors. BACKGROUND: A common hallmark of cancer is the alteration of cellular metabolism. To sustain growth and proliferation, cancer cells must produce sufficient and balanced pools of deoxyribonucleotide...

Published: 7/19/2023 | Inventor(s): Caius Radu, Evan Abt, Thuc Le

Keywords(s): Oncology (Small Molecules, Peptides and Antibodies)

Category(s): Therapeutics > Oncology > Oncology (Small Molecules)